The following changes made to the P3 trial suggests it was made at the request of the FDA. This could've also been the reason for the lengthy IND delays, the back and forth around use of 2 mg vs 1.5 mg. A real shame.
https://classic.clinicaltrials.gov/ct2/history/NCT04809376?A=1&B=2&C=Side-by-Side#StudyPageTop
AGM 2024 - QUESTIONS, page-47
-
- There are more pages in this discussion • 105 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
-0.015(6.38%) |
Mkt cap ! $76.95M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 22.0¢ | $116.8K | 504.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 166525 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 87212 | 5 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |